Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M25.8Revenue $M0.0Net Margin (%)-91,429.4Z-Score-8.8
Enterprise Value $M24.3EPS $-3.1Operating Margin %-74,217.7F-Score4
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-91,429.4Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %-29.3Quick Ratio0.9Cash flow > EarningsY
Price/Sales1,3995-y EBITDA Growth Rate %5.7Current Ratio0.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-79.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-94.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M12.6ROI % (ttm)-120.6Gross Margin Increase y-yN

Gurus Latest Trades with ECTE

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ECTE is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ECTE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nordlicht Mark10% Owner 2014-06-30Buy65,739$2.2-5.91view
Nordlicht Mark10% Owner 2014-06-26Buy17,300$2.2-5.91view
Nordlicht Mark10% Owner 2014-06-24Buy16,961$2.2-5.91view
GOLDBERG MICHAEL M 2014-02-28Sell0$0-5.91view
Nordlicht Mark10% Owner 2013-12-10Buy69,569$2.75-24.73view
Platinum Partners Value Arbitr10% Owner 2013-07-11Sell0$0-24.73view
Doman Robert FDirector 2013-03-22Buy15,000$0.8158.75view
GRIECO WILLIAMDirector 2013-03-21Buy30,000$0.76172.37view
SMITH JAMES FRANCISDirector 2012-08-23Buy20,000$1.4740.82view
BURKE KIMBERLY A 2011-10-13Sell0$040.82view

Press Releases about ECTE :

    Quarterly/Annual Reports about ECTE:

    News about ECTE:

    Articles On GuruFocus.com
    5 Healthcare Picks for 2012 Mar 21 2012 


    More From Other Websites
    Echo Therapeutics Restores Pact with MTIA, Issues Patent - Analyst Blog Jan 22 2015
    Echo Therapeutics and Medical Technologies Innovation Asia (MTIA) Re-affirm Operational Partnership Jan 21 2015
    ECHO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2015
    Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Jan 06 2015
    Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy Jan 06 2015
    CFO Moves: Echo Therapeutics, ADVA, Tanzanian Royalty Exploration, Westaim, Ansal Properties Jan 02 2015
    ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 30 2014
    Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer Dec 30 2014
    Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer Dec 30 2014
    Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer Dec 23 2014
    Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer Dec 23 2014
    ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Dec 19 2014
    ECHO THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Dec 12 2014
    ECHO THERAPEUTICS, INC. Financials Nov 27 2014
    ECHO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 26 2014
    10-Q/A for Echo Therapeutics, Inc. Nov 22 2014
    10-Q for Echo Therapeutics, Inc. Nov 21 2014
    ECHO THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report Nov 20 2014
    Echo Therapeutics Announces Third Quarter 2014 Financial Results Nov 19 2014
    Echo Therapeutics Announces Third Quarter 2014 Financial Results Nov 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK